The success experienced by Seattle Genetics is something that cannot be ignored in the business world. Not only is Seattle Genetics challenging industry standards, but the company is making great strides in the development of pharmaceuticals to treat certain cancers. Recently, Seattlebusinessmag.com sat down to discuss the company’s enormous success with co-founder and President Clay Siegall. Since he helped co-found the company in 1998, Seattle Genetics has enjoyed steady growth and prosperity under his leadership. Siegel credits the growth to his mantra “never take no for an answer” and his unbelievable motivation towards developing cancer relief drugs. Siegall also explains that early in the development of Seattle Genetics, he borrowed a lot of business strategy from his mentor Art Levinson from Genentech. He appreciated the way that Levinson organized Genentech, and he adapted it to meet his needs with Seattle Genetics. Genentech became very successful under Levinson’s leadership and Siegall wanted that for his small company as well. Over the years Seattle Genetics has risen to because of the biggest biotechnology company in Washington state, but Siegall has his eye on even bigger expansion into big pharmacology. The hope is that while Seattle Genetics will continue to develop drugs with the benevolence that they always have, the will be able to break into a bigger stage where they are able to do more good for the public.
Clay Siegall has not always been the fearless leader of this powerhouse pharmaceutical company. Before he founded Seattle Genetics, he worked for several biotechnology companies. This important time in his career left him with the skills he needs to become a successful businessman in his field. Throughout his work, it is evident that he is not only interested in success but that he takes the responsibility of his position very seriously. He is always looking for ways to improve Seattle Genetics and take it to the next level. In fact, in 2001 he was able to secure financing for Seattle Genetics to the tune of $675 million dollars after vigorous fund-raising activities.
While Clay Siegall grows his company, he is also proving that he is a seasoned veteran of his field and an expert. With a Ph.D. in Genetics from George Washington University, he has never been afraid to learn. As he continues his work, he relies on the knowledge he has gained to set him apart from his peers and forge his path through the biotech industry. He will continue to do amazing things in the future.